Biotech - Drug Development
Biotechnology companies developing novel therapeutics across disease areas (excluding oncology-focused)
Rare Disease Therapeutics152
Neuroscience & CNS90
Immunology & Autoimmune80
Metabolic & Cardiometabolic42
Infectious Disease & Vaccines51
Clinical-Stage Platforms149
 LLY | Eli Lilly & Co. | Metabolic & Cardiometabolic | $1.0t | $1211.50 | +7.4% | 5.3M |
 JNJ | Johnson & Johnson | Immunology & Autoimmune | $0.5t | $254.38 | +4.0% | 9.7M |
 ABBV | ABBVIE INC. | Immunology & Autoimmune | $384.7b | $252.95 | +4.1% | 11.1M |
 MRK | Merck & Co., Inc. | Infectious Disease & Vaccines | $293.2b | $128.22 | +1.7% | 9.8M |
 AZN | AstraZeneca PLC | Metabolic & Cardiometabolic | $287.9b | $188.18 | +1.5% | 2.5M |
 TMO | Thermo Fisher Scientific, Inc. | Clinical-Stage Platforms | $183.0b | $509.73 | +1.4% | 2.9M |
 AMGN | Amgen Inc | Rare Disease TherapeuticsImmunology & Autoimmune | $181.8b | $357.17 | +1.4% | 1.7M |
 GILD | Gilead Sciences Inc | Infectious Disease & Vaccines | $166.9b | $127.40 | +2.8% | 7.2M |
 PFE | Pfizer Inc. | Infectious Disease & Vaccines | $149.2b | $24.27 | +2.5% | 36.0M |
 BMY | Bristol-Myers Squibb Co. | Immunology & Autoimmune | $116.8b | $57.40 | +3.8% | 9.2M |
 VRTX | Vertex Pharmaceuticals Inc | Rare Disease Therapeutics | $113.6b | $489.29 | +2.3% | 3.0M |
 REGN | Regeneron Pharmaceuticals Inc | Immunology & Autoimmune | $64.5b | $629.25 | +2.1% | 689.1K |
 ALNY | Alnylam Pharmaceuticals, Inc. | Rare Disease Therapeutics | $40.3b | $291.25 | -0.5% | 760.7K |
 A | Agilent Technologies Inc. | Clinical-Stage Platforms | $38.2b | $134.42 | +0.4% | 1.6M |
 WAT | Waters Corp | Clinical-Stage Platforms | $37.7b | $374.51 | -0.7% | 795.5K |
 IQV | IQVIA Holdings Inc. | Clinical-Stage Platforms | $30.4b | $189.16 | +2.5% | 1.0M |
 BIIB | Biogen Inc. Common Stock | Neuroscience & CNS | $28.9b | $215.50 | +7.0% | 1.4M |
 RPRX | Royalty Pharma plc Class A Ordinary Shares | Clinical-Stage Platforms | $24.7b | $55.59 | +2.9% | 4.4M |
 UTHR | United Therapeutics Corp | Rare Disease Therapeutics | $23.6b | $542.50 | -0.2% | 431.9K |
 INSM | Insmed, Inc. | Rare Disease Therapeutics | $23.2b | $104.75 | -0.9% | 3.4M |
 WST | West Pharmaceutical Services, Inc. | Clinical-Stage Platforms | $22.8b | $350.73 | +1.2% | 672.2K |
 ROIV | Roivant Sciences Ltd. Common Shares | Immunology & Autoimmune | $21.6b | $34.06 | +0.1% | 6.4M |
 INCY | Incyte Genomics Inc | Rare Disease Therapeutics | $19.3b | $112.75 | +5.8% | 2.2M |
 MRNA | Moderna, Inc. Common Stock | Infectious Disease & Vaccines | $18.7b | $67.14 | +12.6% | 12.8M |
 NBIX | Neurocrine Biosciences Inc | Neuroscience & CNS | $15.9b | $165.64 | +2.7% | 1.2M |
 JAZZ | Jazz Pharmaceuticals, Inc. | Neuroscience & CNS | $14.8b | $229.94 | +1.7% | 517.2K |
 ASND | Ascendis Pharma A/S Ordinary Share | Clinical-Stage Platforms | $13.8b | $261.05 | -0.2% | 922.2K |
 SMMT | Summit Therapeutics Inc. Common Stock | Infectious Disease & Vaccines | $13.6b | $14.11 | -1.1% | 2.6M |
 BBIO | BridgeBio Pharma, Inc. Common Stock | Rare Disease Therapeutics | $13.0b | $70.87 | +0.9% | 5.3M |
 MEDP | Medpace Holdings, Inc. Common Stock | Clinical-Stage Platforms | $12.8b | $523.40 | +1.2% | 264.1K |
 IONS | Ionis Pharmaceuticals, Inc. Common Stock | Rare Disease Therapeutics | $12.6b | $81.19 | +3.7% | 2.7M |
 AXSM | Axsome Therapeutics, Inc | Neuroscience & CNS | $12.1b | $244.88 | +1.8% | 1.5M |
 RGC | Regencell Bioscience Holdings Limited Ordinary Shares | Neuroscience & CNS | $11.8b | $6.38 | -14.8% | 470.2K |
 RVTY | Revvity, Inc. | Clinical-Stage Platforms | $11.7b | $113.03 | -0.4% | 2.4M |
 MDGL | Madrigal Pharmaceuticals, Inc. Common Stock | Metabolic & Cardiometabolic | $11.5b | $508.75 | -0.1% | 400.3K |
 BMRN | BioMarin Pharmaceuticals Inc | Rare Disease Therapeutics | $11.1b | $59.30 | +2.9% | 1.9M |
 ARWR | Arrowhead Research Corporation | Rare Disease Therapeutics | $11.0b | $80.50 | -0.4% | 2.8M |
 CYTK | Cytokinetics Inc. | Rare Disease TherapeuticsNeuroscience & CNS | $10.4b | $82.14 | +1.6% | 3.1M |
 ICLR | Icon Plc | Clinical-Stage Platforms | $10.4b | $169.94 | +5.6% | 1.2M |
 PRAX | Praxis Precision Medicines, Inc. Common Stock | Neuroscience & CNS | $9.8b | $329.69 | -0.0% | 965.6K |
 KRYS | Krystal Biotech, Inc. Common Stock | Rare Disease Therapeutics | $9.1b | $366.76 | +3.3% | 464.7K |
 BRKR | Bruker Corporation | Clinical-Stage Platforms | $9.0b | $61.00 | +0.1% | 1.4M |
 CRL | Charles River Laboratories International, Inc. | Clinical-Stage Platforms | $8.7b | $213.05 | +1.4% | 1.0M |
 BIO.B | Bio-Rad Laboratories, Inc. Class B | Clinical-Stage Platforms | $8.1b | $299.40 | 0.0% | 11 |
 TECH | Bio-Techne Corp. | Clinical-Stage Platforms | $8.1b | $70.42 | +0.4% | 10.2M |
 HALO | Halozyme Therapeutics, Inc. | Clinical-Stage Platforms | $7.9b | $75.08 | +3.2% | 1.7M |
 IBRX | ImmunityBio, Inc. Common Stock | Immunology & Autoimmune | $7.9b | $8.48 | +11.6% | 23.1M |
 QGEN | QIAGEN N.V. | Clinical-Stage Platforms | $7.5b | $39.00 | +1.2% | 2.7M |
 CORT | Corcept Therapeutics Inc. | Rare Disease Therapeutics | $7.5b | $86.66 | +3.1% | 616.3K |
 PCVX | Vaxcyte, Inc. Common Stock | Infectious Disease & Vaccines | $7.4b | $51.20 | +5.2% | 2.6M |